Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | CPA2 | P48052 | 1/20 | 0.44 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 12/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | PRKAR2A | P13861 | 5/20 | 0.41 |
| ▸ | PRKAR2B | P31323 | 5/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18752938 | 0.87 | LTA4H (0.40) | CCKBR | |
| SCHEMBL16386142 | 0.85 | CCKBR (0.44) | GLP1RSCTRCCKBRAPLNR | |
| SCHEMBL13315238 | 0.85 | CCKBR (0.44) | GLP1RSCTRCCKBRAPLNR | |
| SCHEMBL16386135 | 0.85 | GRPR (0.45) | GLP1RSCTRCCKBRAPLNR | |
| SCHEMBL13315208 | 0.83 | CCKBR (0.42) | GLP1RSCTRCCKBRAPLNR | |
| SCHEMBL18286725 | 0.82 | BACE1 (0.46) | — | |
| SCHEMBL30974282 | 0.81 | OPRD1 (0.46) | GLP1RSCTRCCKBR | |
| SCHEMBL30974011 | 0.81 | OPRD1 (0.49) | CCKBR | |
| SCHEMBL13315229 | 0.81 | PSMB5 (0.47) | GLP1RCCKBRAPLNR | |
| SCHEMBL19387823 | 0.81 | PSMB5 (0.47) | GLP1RCCKBRAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | CPA1 2037/4885CPA2 2983/4885CPA4 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.